West Pharmaceutical director awarded 791 RSUs

BUTHMAN MARK A reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

BUTHMAN MARK A reported acquisition or exercise transactions in this Form 4 filing.

West Pharmaceutical Services Inc. director Mark A. Buthman received an equity award of 791 shares of common stock. The shares were granted at a price of $0.00 per share as a form of compensation, not an open-market purchase.

These shares are in the form of restricted stock units that will vest in full on the date of the next annual shareholder meeting. After this grant, Buthman directly holds a total of 44,308.5494 shares of West Pharmaceutical common stock.

Insider Trade Summary

Grant/Award: 791 shares

Grant/Award 1 txn

Insider BUTHMAN MARK A

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	791	$0.00	$0.00

Holdings After Transaction: Common Stock — 44,308.5494 shares (Direct)

Footnotes (1)

1. F1. These shares of restricted stock units will vest in full on the date of the next annual shareholder meeting.

Key Figures

RSU grant size: 791 shares Grant price per share: $0.00 per share Shares held after transaction: 44,308.5494 shares +2 more

5 metrics

RSU grant size 791 shares Restricted stock units granted to director on 2026-05-04

Grant price per share $0.00 per share Compensation award, not open-market purchase

Shares held after transaction 44,308.5494 shares Total direct holdings following the RSU grant

Vesting trigger Next annual shareholder meeting RSUs vest in full on that meeting date

Transaction code A Grant, award, or other acquisition of shares

Key Terms

restricted stock units, annual shareholder meeting, grant, award, or other acquisition, Form 4

4 terms

restricted stock units financial

"These shares of restricted stock units will vest in full on the date"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

annual shareholder meeting financial

"will vest in full on the date of the next annual shareholder meeting"

A yearly gathering where a company’s owners (shareholders) and its leaders meet to review performance, approve key decisions like electing directors, and vote on issues such as executive pay or major policy changes. Think of it as an annual town hall for people who own part of the business: investors use it to ask questions, influence direction through votes, and gauge management’s plans and transparency, all of which can affect the stock’s outlook.

grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did West Pharmaceutical (WST) director Mark A. Buthman report in this Form 4?

Director Mark A. Buthman reported receiving an award of 791 shares of West Pharmaceutical common stock. These shares were granted as restricted stock units at $0.00 per share and are a form of equity compensation, not an open-market stock purchase.

Is the 791-share transaction for West Pharmaceutical (WST) a stock purchase or an award?

The 791-share transaction is an equity award, not an open-market stock purchase. It is coded as a grant or award acquisition, with a transaction price of $0.00 per share, reflecting restricted stock units granted as compensation to director Mark A. Buthman.

When will the 791 restricted stock units for West Pharmaceutical (WST) vest?

The 791 restricted stock units granted to director Mark A. Buthman will vest in full on the date of West Pharmaceutical’s next annual shareholder meeting. Until vesting, they remain restricted stock units rather than fully unrestricted common shares.

How many West Pharmaceutical (WST) shares does Mark A. Buthman hold after this award?

After the 791-share award, Mark A. Buthman directly holds 44,308.5494 shares of West Pharmaceutical common stock. This total reflects his direct ownership following the reported grant of restricted stock units on the transaction date.

What does transaction code 'A' mean in this West Pharmaceutical (WST) Form 4?

Transaction code 'A' on this Form 4 indicates a grant, award, or other acquisition of shares. For West Pharmaceutical director Mark A. Buthman, it represents a compensation-related award of 791 restricted stock units rather than an open-market buy or sell trade.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/06/2026 - 05:18 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BUTHMAN MARK A

(Last) (First) (Middle)

530 HERMAN O. WEST DRIVE

(Street)

EXTON PENNSYLVANIA 19341

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
WEST PHARMACEUTICAL SERVICES INC [ WST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/04/2026		A		791(1)	A	$0	44,308.5494	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares of restricted stock units will vest in full on the date of the next annual shareholder meeting.

	/s/ Louis Lalli, as an agent for Mark A. Buthman	05/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)